Glaxo Wellcome acquisition of Polfa Polzan creates largest Rx company in Poland.
Executive Summary
GLAXO TO EXPAND EASTERN/CENTRAL EUROPE PRESENCE VIA ACQUISITION OF POLISH DRUG FIRM Polfa Poznan SA. Glaxo Wellcome announced Jan. 28 an agreement to acquire 80% of Poland's second largest pharmaceutical company from the Polish Ministry of State Treasury. The combination of Polfa Poznan with the existing Glaxo Wellcome Poland will make Glaxo Wellcome Poznan the largest pharmaceutical company in Poland, with a 7.5% market share. The deal allows Glaxo "to expand its base throughout Eastern and Central Europe and other emerging markets," the company said, noting a "strong commitment to its regionalization strategy and the importance of emerging markets to the company's future development."
You may also be interested in...
EMEA/Eastern Block To Form Drug Regulation Action Plan In February
EU regulators and their counterparts from Central and Eastern European countries will meet in Budapest in early February to form an action plan for the European Commission's Pan-European Regulatory Forum (PERF) for pharmaceuticals.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011